Restricted accessResearch articleFirst published online 2011-08
RGSZ2 Binds to the Neural Nitric Oxide Synthase PDZ Domain to Regulate Mu-Opioid Receptor-Mediated Potentiation of the N -Methyl-D-Aspartate Receptor-Calmodulin-Dependent Protein Kinase II Pathway
Morphine increases the production of nitric oxide (NO) via the phosphoinositide 3-kinase/Akt/neural nitric oxide synthase (nNOS) pathway. Subsequently, NO enhances N-methyl-D-aspartate receptor (NMDAR)/calmodulin-dependent protein kinase II (CaMKII) cascade, diminishing the strength of morphine-activated Mu-opioid receptor (MOR) signaling. During this process, NO signaling is restricted by the association of nNOS to the MOR. Aims: Here, we examined how nNOS/NO signaling is downregulated by the morphine-activated MOR and how this regulation affects antinociception. Results: Accordingly, we show that the MOR-NMDAR regulatory loop relies on the negative control of nNOS activity exerted by RGSZ2, a protein physically coupled to the MOR. This regulation requires binding of the nNOS N terminal PDZ domain to the RGSZ2 PDZ binding motifs that lie upstream of the RGS box. Innovation: Indeed, in RGSZ2-deficient mice morphine over-stimulates the nNOS/NO/NMDAR/CaMKII pathway, causing analgesic tolerance to develop rapidly. Recovery of RGSZ2 levels or inhibition of nNOS, protein kinase C, NMDAR, or CaMKII function restores MOR signaling and morphine recovers its full analgesic potency. Conclusion: This RGSZ2-dependent regulation of NMDAR activity is relevant to persistent pain disorders associated with heightened NMDAR-mediated glutamate responses and the reduced antinociceptive capacity of opioids. Antioxid. Redox Signal. 15, 873–887.
Get full access to this article
View all access options for this article.
References
1.
AiW, GongJ, YuL. MAP kinase activation by mu opioid receptor involves phosphatidylinositol 3-kinase but not the cAMP/PKA pathway. FEBS Lett, 456:196–200. 1999.
2.
AjitSK, RamineniS, EdrisW, HuntRA, HumWT, HeplerJR, YoungKH. RGSZ1 interacts with protein kinase C interacting protein PKCI-1 and modulates mu opioid receptor signaling. Cell Signal, 19:723–730. 2007.
3.
BleakmanD, AltA, NisenbaumES. Glutamate receptors and pain. Semin Cell Dev Biol, 17:592–604. 2006.
4.
BraithwaiteSP, PaulS, NairnAC, LombrosoPJ. Synaptic plasticity: one STEP at a time. Trends Neurosci, 29:452–458. 2006.
5.
BrenmanJE, ChaoDS, GeeSH, McGeeAW, CravenSE, SantillanoDR, WuZ, HuangF, XiaH, PetersMF, FroehnerSC, BredtDS. Interaction of nitric oxide synthase with the postsynaptic density protein PSD-95 and alpha1-syntrophin mediated by PDZ domains. Cell, 84:757–767. 1996.
6.
BrennerGJ, JiRR, ShafferS, WoolfCJ. Peripheral noxious stimulation induces phosphorylation of the NMDA receptor NR1 subunit at the PKC-dependent site, serine-896, in spinal cord dorsal horn neurons. Eur J Neurosci, 20:375–384. 2004.
7.
ChakrabartiS, LiuNJ, GintzlerAR. Reciprocal modulation of phospholipase Cβ isoforms: adaptation to chronic morphine. Proc Natl Acad Sci U S A, 100:13686–13691. 2003.
8.
ChenL, HuangLY. Sustained potentiation of NMDA receptor-mediated glutamate responses through activation of protein kinase C by a μ opioid. Neuron, 7:319–326. 1991.
9.
CommonsKG, van BockstaeleEJ, PfaffDW. Frequent colocalization of mu opioid and NMDA-type glutamate receptors at postsynaptic sites in periaqueductal gray neurons. J Comp Neurol, 408:549–559. 1999.
10.
DaffS. NO synthase: structures and mechanisms. Nitric Oxide, 23:1–11. 2010.
11.
DoyleGA, FurlongPJ, SchwebelCL, SmithGG, LohoffFW, BuonoRJ, BerrettiniWH, FerraroTN. Fine mapping of a major QTL influencing morphine preference in C57BL/6 and DBA/2 mice using congenic strains. Neuropsychopharmacology, 33:2801–2809. 2008.
12.
DunkleyPR, JarviePE, RobinsonPJ. A rapid Percoll gradient procedure for preparation of synaptosomes. Nat Protoc, 3:1718–1728. 2008.
13.
ElliottK, MinamiN, KolesnikovYA, PasternakGW, InturrisiCE. The NMDA receptor antagonists, LY274614 and MK-801, and the nitric oxide synthase inhibitor, NG-nitro-L-arginine, attenuate analgesic tolerance to the mu-opioid morphine but not to kappa opioids. Pain, 56:69–75. 1994.
14.
FisherK, CoderreTJ, HagenNA. Targeting the N-methyl-D-aspartate receptor for chronic pain management. Preclinical animal studies, recent clinical experience and future research directions. J Pain Symptom Manage, 20:358–373. 2000.
15.
GarzónJ, Rodríguez-MuñozM, López-FandoA, Sánchez-BlázquezP. The RGSZ2 protein exists in a complex with mu-opioid receptors and regulates the desensitizing capacity of Gz proteins. Neuropsychopharmacology, 30:1632–1648. 2005.
16.
GarzónJ, Rodríguez-MuñozM, Sánchez-BlázquezP. Do pharmacological approaches that prevent opioid tolerance target different elements in the same regulatory machinery?Curr Drug Abuse Rev, 1:222–238. 2008.
17.
GlassMJ, VanyoL, QuimsonL, PickelVM. Ultrastructural relationship between N-methyl-D-aspartate-NR1 receptor subunit and mu-opioid receptor in the mouse central nucleus of the amygdala. Neuroscience, 163:857–867. 2009.
18.
GuangW, WangH, SuT, WeinsteinIB, WangJB. Role of mPKCI, a novel mu-opioid receptor interactive protein, in receptor desensitization, phosphorylation, and morphine-induced analgesia. Mol Pharmacol, 66:1285–1292. 2004.
19.
HeoJ, CampbellSL. Ras regulation by reactive oxygen and nitrogen species. Biochemistry, 45:2200–2210. 2006.
20.
InoueM, MishinaM, UedaH. Locus-specific rescue of GluRɛ1 NMDA receptors in mutant mice identifies the brain regions important for morphine tolerance and dependence. J Neurosci, 23:6529–6536. 2003.
21.
KissinI, BrightCA, BradleyEL.Jr. The effect of ketamine on opioid-induced acute tolerance: can it explain reduction of opioid consumption with ketamine-opioid analgesic combinations?Anesth Analg, 91:1483–1488. 2000.
22.
KolesnikovY, JainS, WilsonR, PasternakGW. Lack of morphine and enkephalin tolerance in 129/SvEv mice: evidence for a NMDA receptor defect. J Pharmacol Exp Ther, 284:455–459. 1998.
23.
KowLM, CommonsKG, OgawaS, PfaffDW. Potentiation of the excitatory action of NMDA in ventrolateral periaqueductal gray by the mu-opioid receptor agonist, DAMGO. Brain Res, 935:87–102. 2002.
24.
KoyamaS, AkaikeN. Activation of mu-opioid receptor selectively potentiates NMDA-induced outward currents in rat locus coeruleus neurons. Neurosci Res, 60:22–28. 2008.
25.
LeakTS, MychaleckyjJC, SmithSG, KeeneKL, GordonCJ, HicksPJ, FreedmanBI, BowdenDW, SaleMM. Evaluation of a SNP map of 6q24-27 confirms diabetic nephropathy loci and identifies novel associations in type 2 diabetes patients with nephropathy from an African-American population. Hum Genet, 124:63–71. 2008.
26.
LuWY, XiongZG, LeiS, OrserBA, DudekE, BrowningMD, MacDonaldJF. G-protein-coupled receptors act via protein kinase C and Src to regulate NMDA receptors. Nat Neurosci, 2:331–338. 1999.
27.
LuginbuhlM, GerberA, SchniderTW, Petersen-FelixS, Arendt-NielsenL, CuratoloM. Modulation of remifentanil-induced analgesia, hyperalgesia, and tolerance by small-dose ketamine in humans. Anesth Analg, 96:726–732. 2003.
MarekP, Ben-EliyahuS, VaccarinoAL, LiebeskindJC. Delayed application of MK-801 attenuates development of morphine tolerance in rats. Brain Res, 558:163–165. 1991.
30.
MurthyKS, MakhloufGM. Opioid mu, delta, and kappa receptor-induced activation of phospholipase C-beta 3 and inhibition of adenylyl cyclase is mediated by Gi2 and G(o) in smooth muscle. Mol Pharmacol, 50:870–877. 1996.
31.
NaritaM, HashimotoK, AmanoT, NaritaM, NiikuraK, NakamuraA, SuzukiT. Post-synaptic action of morphine on glutamatergic neuronal transmission related to the descending antinociceptive pathway in the rat thalamus. J Neurochem, 104:469–478. 2008.
32.
PasternakGW, KolesnikovYA, BabeyAM. Perspectives on the N-methyl-D-aspartate/nitric oxide cascade and opioid tolerance. Neuropsychopharmacology, 13:309–313. 1995.
33.
RameauGA, TukeyDS, Garcin-HosfieldED, TitcombeRF, MisraC, KhatriL, GetzoffED, ZiffEB. Biphasic coupling of neuronal nitric oxide synthase phosphorylation to the NMDA receptor regulates AMPA receptor trafficking and neuronal cell death. J Neurosci, 27:3445–3455. 2007.
34.
Rodríguez-MuñozM, BermúdezD, Sánchez-BlázquezP, GarzónJ. Sumoylated RGS-Rz proteins act as scaffolds for Mu-opioid receptors and G-protein complexes in mouse brain. Neuropsychopharmacology, 32:842–850. 2007.
35.
Rodríguez-MuñozM, de laTorre-Madrid E, Sánchez-BlázquezP, GarzónJ. Morphine induces endocytosis of neuronal mu-opioid receptors through the sustained transfer of Galpha subunits to RGSZ2 proteins. Mol Pain, 3:19. 2007.
36.
Rodríguez-MuñozM, de laTorre-Madrid E, Sánchez-BlázquezP, WangJB, GarzónJ. NMDAR-nNOS generated zinc recruits PKCgamma to the HINT1-RGS17 complex bound to the C terminus of Mu-opioid receptors. Cell Signal, 20:1855–1864. 2008.
37.
Rodríguez-MuñozM, Sánchez-BlázquezP, Vicente-SánchezA, BailónC, Martín-AznarB, GarzónJ. The histidine triad nucleotide-binding protein 1 supports mu-opioid receptor-glutamate NMDA receptor cross-regulation. Cell Mol Life Sci DOI:10.1007/s00018-010-0598-x2010.
38.
Sánchez-BlázquezP, Rodríguez-MuñozM, de la Torre-MadridE, GarzónJ. Brain-specific Gαz interacts with Src tyrosine kinase to regulate Mu-opioid receptor-NMDAR signaling pathway. Cell Signal, 21:1444–1454. 2009.
39.
Sánchez-BlázquezP, Rodríguez-MuñozM, GarzónJ. Mu-opioid receptors transiently activate the Akt-nNOS pathway to produce sustained potentiation of PKC-mediated NMDAR-CaMKII signaling. PLoS ONE, 5:e11278. 2010.
40.
Sánchez-BlázquezP, Rodríguez-MuñozM, MonteroC, de la Torre-MadridE, GarzónJ. Calcium/calmodulin-dependent protein kinase II supports morphine antinociceptive tolerance by phosphorylation of glycosylated phosducin-like protein. Neuropharmacology, 54:319–330. 2008.
41.
SaperCB, SawchenkoPE. Magic peptides, magic antibodies: guidelines for appropriate controls for immunohistochemistry. J Comp Neurol, 465:161–163. 2003.
SerranoJ, FernandezAP, SánchezJ, RodrigoJ, MartínezA. Adrenomedullin expression is up-regulated by acute hypobaric hypoxia in the cerebral cortex of the adult rat. Brain Pathol, 18:434–442. 2008.
44.
SierraDA, GilbertDJ, HouseholderD, GrishinNV, YuK, UkidweP, BarkerSA, HeW, WenselTG, OteroG, BrownG, CopelandNG, JenkinsNA, WilkieTM. Evolution of the regulators of G-protein signaling multigene family in mouse and human. Genomics, 79:177–185. 2002.
45.
TochioH, ZhangQ, MandalP, LiM, ZhangM. Solution structure of the extended neuronal nitric oxide synthase PDZ domain complexed with an associated peptide. Nat Struct Biol, 6:417–421. 1999.
46.
TrujilloKA, AkilH. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science, 251:85–87. 1991.
47.
YakshTL, YeungJC, RudyTA. Systematic examination in the rat of brain sites sensitive to the direct application of morphine: observation of differential effects within the periaqueductal gray. Brain Res, 114:83–103. 1976.
48.
YunHY, Gonzalez-ZuluetaM, DawsonVL, DawsonTM. Nitric oxide mediates N-methyl-D-aspartate receptor-induced activation of p21ras. Proc Natl Acad Sci U S A, 95:5773–5778. 1998.
ZhuJJ, QinY, ZhaoM, VanAL, MalinowR. Ras and Rap control AMPA receptor trafficking during synaptic plasticity. Cell, 110:443–455. 2002.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
